NGS has been applied to identify actionable mutations and personalize treatments to target genetic variants for cancer patients. Clinical results have showed that patients treated with sequencing-matched therapies had improved overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), progression free survival (PFS) and tumor response rate (TRR).